It can reverse the resistance of NSCLC cells to erlotinib and abrogate PD-L1 expression, which mediates immune checkpoint blockade therapy in NSCLC.317 Another two approved JAK inhibitors are tofacitinib and baricitinib.318,319 They are all used clinically for the treatment of autoimmune diseases.313. This evidence concerns the gene CD274 and non-small cell lung carcinoma.